Urology Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
Urology Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy -
Minerva Urol Nephrol. 2021 Jun;73(3):349-356. doi: 10.23736/S2724-6051.20.03646-2. Epub 2020 Jan 30.
The aim of this study was to analyze the incidence, preoperative findings, pathological features and prognosis in patients with incidental prostate cancer (iPCa) detected at radical cystectomy (RC) for bladder cancer (BCa).
We retrospectively reviewed data of patients who underwent RC for BCa at our Institution between January 2005 and March 2018. Data regarding patient's history, preoperative digital rectal examination (DRE), total serum PSA level were collected from the chart review. Univariable and multivariable Cox regression models addressed the association of iPCa with recurrence-free survival (RFS) and overall survival (OS).
We obtained a final study cohort of 177 patients. Median age was 69 years (IQR 42-89) and 80(45.2%) patients had iPCa. Patients with iPCa had higher age, preoperative PSA levels and a significant rate of suspicious DRE (all P<0.05). Four patients had BCR during a median follow-up of 28 months (IQR 6-159) and none died for prostate cancer. In multivariable analyses adjusted for age, bladder cancer BCa pT and pN stage and LVI the ten-years RFS and OS rates were not impacted by iPCa regardless of whether it is a clinically significant cancer or not (HR=1.25, 95% CI: 0.65-2.38, P=0.51 vs. HR=1.37, 95% CI: 0.71-2.64, P=0.35) (HR=1.04, 95% CI: 0.53-1.86, P=0.89 vs. HR=1.20, 95% CI: 0.22-6.72, P=0.83).
iPCa is quite common in our study group and most of cases are organ-confined and well differentiated. Regardless of clinical relevance, iPCa does not have an impact on survival outcomes as BCa is driving the prognosis of these patients.
本研究旨在分析在膀胱癌(BCa)根治性膀胱切除术(RC)中偶然发现的前列腺癌(iPCa)患者的发病率、术前发现、病理特征和预后。
我们回顾性分析了 2005 年 1 月至 2018 年 3 月期间在我院接受 RC 治疗 BCa 的患者数据。从图表回顾中收集了患者病史、术前直肠指检(DRE)、总血清 PSA 水平等数据。单变量和多变量 Cox 回归模型探讨了 iPCa 与无复发生存率(RFS)和总生存率(OS)的关系。
我们获得了一个最终的研究队列,共 177 名患者。中位年龄为 69 岁(IQR 42-89),80 名(45.2%)患者患有 iPCa。iPCa 患者年龄较大,术前 PSA 水平较高,DRE 可疑率较高(均 P<0.05)。4 名患者在中位随访 28 个月(IQR 6-159)时发生 BCR,无患者死于前列腺癌。在调整年龄、膀胱癌 BCa pT 和 pN 分期和 LVI 后,多变量分析显示,无论 iPCa 是否为临床显著癌症,10 年 RFS 和 OS 率不受影响(HR=1.25,95%CI:0.65-2.38,P=0.51 比 HR=1.37,95%CI:0.71-2.64,P=0.35)(HR=1.04,95%CI:0.53-1.86,P=0.89 比 HR=1.20,95%CI:0.22-6.72,P=0.83)。
在我们的研究组中,iPCa 相当常见,大多数病例为器官局限性和分化良好的。无论临床相关性如何,iPCa 对生存结果没有影响,因为 BCa 是影响这些患者预后的主要因素。